

GT BIOPHARMA, INC.  
9350 Wilshire Blvd.  
Suite 203  
Beverly Hills, CA 90212

February 8, 2021

**Via EDGAR Submission**

United States Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549

**Attention:** **Tim Buchmiller**

**Re:** GT Biopharma, Inc.  
Registration Statement on Form S-1  
CIK No. 0000109657  
SEC Registration No. 333-251311

Ladies and Gentlemen:

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-251311) (the "Registration Statement") of GT Biopharma, Inc. (the "Company"). We respectfully request that the Registration Statement become effective as of 5:00 p.m., Eastern Time, on February 10, 2021, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Baker & McKenzie LLP by calling Roger Bivans at (214) 978-3095.

Thank you for your assistance with this matter.

Very truly yours,

/s/ Michael Handelman  
\_\_\_\_\_  
Michael Handelman  
Chief Financial Officer

---